dalteparin has been researched along with Cardiovascular Diseases in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 14 (48.28) | 29.6817 |
| 2010's | 9 (31.03) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Reĭko, MN; Shchupak, MB; Sidorenko, PI; Sirenko, IuN; Sychev, OS | 1 |
| Bernardi, E; Camporese, G; Noventa, F | 1 |
| Keating, GM; McKeage, K | 1 |
| Barco, S; Bingisser, R; Colucci, G; Duerschmied, D; Fumagalli, RM; Gerber, B; Götschi, A; Hasse, B; Held, U; Keller, DI; Konstantinides, SV; Kucher, N; Mach, F; Rampini, SK; Righini, M; Robert-Ebadi, H; Rosemann, T; Roth-Zetzsche, S; Sebastian, T; Simon, NR; Spirk, D; Stortecky, S; Vaisnora, L; Voci, D | 1 |
| Almaghaslah, D; Khaled, A; Makki, S; Nagib, R; Siddiqua, A | 1 |
| Bianco, G; Boari, GEM; Bonetti, S; Bonzi, B; Braglia-Orlandini, F; Chiarini, G; Desenzani, P; Faustini, C; Ferrari-Toninelli, G; Guarinoni, V; Malerba, P; Mascadri, C; Nardin, M; Pasini, G; Rizzoni, D; Saottini, M; Turini, D; Tusi, C; Viola, S; Zanotti, E | 1 |
| Arbetter, D; Chi, G; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, R; Jain, P; Korjian, S; Lopes, RD | 1 |
| Acar, R; Erturk, I; Ozgurtas, T; Saglam, K; Yesildal, F | 1 |
| Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA | 1 |
| Albaladejo, P; Beyer-Westendorf, J; Bronson, MD; Cohen, AT; Conley, PB; Connolly, SJ; Crowther, M; Curnutte, JT; Eikelboom, JW; Gibson, CM; Gold, A; Goodman, S; Leeds, J; Lim, WT; Lopez-Sendon, J; Lu, G; Meeks, B; Middeldorp, S; Milling, TJ; Nakamya, J; Schmidt, J; Siegal, DM; Verhamme, P; Wiens, BL; Zotova, E | 1 |
| Boiangiu, C; Cohen, M; Kaid, K; Khalid, K; Khoobiar, S; Mejevoi, N; Setty, S; Tanwir, A | 1 |
| Bauer, T; Gitt, A; Heer, T; Jünger, C; Koeth, O; Senges, J; Zahn, R; Zeymer, U | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R | 1 |
| Pendleton, RC; Rodgers, GM; Smock, KJ; Wilcox, R | 1 |
| Hoffmann, P; Keller, F | 1 |
| Altun, A; Karahan, O; Katrancioglu, N; Katrancioglu, O; Kilic, AT; Polat, ZA | 1 |
| Biteker, M; Can, MM; Dayan, A; Ilhan, E; Tekkeşin, Aİ; Türkmen, FM | 1 |
| Bergmann, JF; Mouly, S | 1 |
| Chow, SL; Dannenhoffer, M; Lopez-Candales, A; West, K; Zammit, K | 1 |
| Daniel, WG; Geller, C; Hanrath, P; Hofmann, T; Lehmacher, W; Mügge, A; Nixdorff, U; Schmidt-Lucke, C; Schmidt-Lucke, JA; Sehnert, W; Stellbrink, C | 1 |
| Chazova, IE; Dvoskina, IM; Gornostaev, VV; Mamyrbaeva, KM; Mychka, VB; Sergienko, VB | 1 |
| Almanric, K; Bazinet, A; Blais, N; Brunet, C; Caron, S; Lalonde, L; Martineau, J; Turcotte, I | 1 |
| Spinler, S | 1 |
| Hamdan, K; Rajagopal, AS; Shinkfield, M; Voight, S | 1 |
| Batisse, A; Batisse, JP; Beygui, F; Choussat, R; Collet, JP; Helft, G; Le Feuvre, C; Metzger, JP; Montalescot, G | 1 |
| Hunt, D | 1 |
| LYDECKER, E; SUSSMAN, I | 1 |
| d'Urso, M; Durand-Gasselin, B; Février, M; Gaussem, P; Laurent, M; Pautas, E; Siguret, V | 1 |
6 review(s) available for dalteparin and Cardiovascular Diseases
| Article | Year |
|---|---|
Update on the clinical use of the low-molecular-weight heparin, parnaparin.
Topics: Acute Coronary Syndrome; Anticoagulants; Arterial Occlusive Diseases; Cardiovascular Diseases; Drug Administration Schedule; Evidence-Based Medicine; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2009 |
Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders.
Topics: Anticoagulants; Cardiovascular Diseases; Chronic Disease; Drug Administration Schedule; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Treatment Outcome; Venous Thromboembolism | 2008 |
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Topics: Antithrombins; Benzimidazoles; Blood Coagulation Tests; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Enoxaparin; Humans; Pyridines; Venous Thromboembolism; Warfarin | 2011 |
Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis.
Topics: Anticoagulants; Cardiovascular Diseases; Enoxaparin; Glomerular Filtration Rate; Hemorrhage; Humans; Renal Insufficiency; Renal Insufficiency, Chronic; Risk; Severity of Illness Index | 2012 |
Thromboprophylaxis in medical patients: focus on France.
Topics: Acute Disease; Adult; Aged; Attitude of Health Personnel; Cardiovascular Diseases; Double-Blind Method; Drug Overdose; Drug Utilization; Enoxaparin; Female; Fibrinolytic Agents; France; Humans; Immobilization; Infections; Lung Diseases; Male; Meta-Analysis as Topic; Middle Aged; Physicians; Practice Patterns, Physicians'; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Pulmonary Embolism; Randomized Controlled Trials as Topic; Risk Factors; Thrombophilia; Thrombosis | 2002 |
Low-molecular-weight heparins in clinical practice.
Topics: Anticoagulants; Cardiovascular Diseases; Clinical Trials as Topic; Dalteparin; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Thromboembolism | 1998 |
9 trial(s) available for dalteparin and Cardiovascular Diseases
| Article | Year |
|---|---|
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Topics: Adult; Anticoagulants; Cardiovascular Diseases; COVID-19; Enoxaparin; Female; Humans; Male; Middle Aged; Outpatients; SARS-CoV-2; Treatment Outcome | 2023 |
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Benzamides; Cardiovascular Diseases; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Inpatients; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Pyridines; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism | 2017 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Infusions, Intravenous; Intracranial Hemorrhages; Male; Prospective Studies; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thrombosis | 2016 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cardiovascular Diseases; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Italy; Male; Middle Aged; Multiple Myeloma; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Thalidomide; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2011 |
Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiovascular Diseases; Enoxaparin; Factor Xa; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Severity of Illness Index | 2003 |
Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE)
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Drug Therapy, Combination; Electric Countershock; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Incidence; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Phenprocoumon; Safety; Thromboembolism; Treatment Outcome | 2004 |
Dosage of enoxaparin among obese and renal impairment patients.
Topics: Aged; Blood Coagulation Tests; Body Weight; Cardiovascular Diseases; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Obesity; Renal Insufficiency | 2005 |
Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Contrast Media; Coronary Angiography; Drug Delivery Systems; Enoxaparin; Female; Humans; Incidence; Ioxaglic Acid; Male; Middle Aged; Osmolar Concentration; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Risk Factors; Stents; Thrombosis; Ticlopidine; Triiodobenzoic Acids | 2006 |
[Monitoring of tinzaparin in a ten day treatment dose in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Creatinine; Drug Administration Schedule; Drug Monitoring; Factor Xa; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Prospective Studies; Prothrombin; Tinzaparin | 2001 |
14 other study(ies) available for dalteparin and Cardiovascular Diseases
| Article | Year |
|---|---|
[The initial experience of using fraxiparin in extracorporeal detoxication in clinical cardiology].
Topics: Anticoagulants; Cardiovascular Diseases; Combined Modality Therapy; Drug Evaluation; Heparin; Humans; Nadroparin; Sorption Detoxification | 1994 |
Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Enoxaparin; Furosemide; Humans; Lisinopril; Ranitidine; Tertiary Care Centers | 2023 |
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Cardiovascular Diseases; Comorbidity; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Prognosis; Retrospective Studies; Risk Factors; Ritonavir; Treatment Outcome | 2020 |
Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Cross-Sectional Studies; Enoxaparin; Erythropoietin; Female; Fibrinolytic Agents; Humans; Insulin; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Injections, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Germany; Hemorrhage; Heparin; Hospital Mortality; Humans; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Registries; Retrospective Studies; Risk Assessment; Treatment Outcome | 2009 |
Comparison of the antiangiogenic effects of heparin sodium, enoxaparin sodium, and tinzaparin sodium by using chorioallantoic membrane assay.
Topics: Angiogenesis Inhibitors; Animals; Anticoagulants; Biological Assay; Cardiovascular Diseases; Chick Embryo; Chickens; Chorioallantoic Membrane; Contraindications; Dose-Response Relationship, Drug; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Neovascularization, Physiologic; Tinzaparin; Zygote | 2012 |
Outcome of noncardiac and nonvascular surgery in patients with mechanical heart valves.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Case-Control Studies; Echocardiography, Transesophageal; Elective Surgical Procedures; Enoxaparin; Female; Follow-Up Studies; Heart Valve Prosthesis; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Prevalence; Prospective Studies; Risk Assessment; Thromboembolism; Treatment Outcome | 2012 |
[Cerebrovascular complications in metabolic syndrome: possible approaches to decrease risk].
Topics: Adult; Anticoagulants; Blood Glucose; Blood Pressure; Body Mass Index; Brain; C-Peptide; Cardiovascular Diseases; Cerebrovascular Circulation; Diabetes Mellitus, Type 2; Enoxaparin; Female; Glucose Tolerance Test; Humans; Hypertension; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Postprandial Period; Radionuclide Imaging; Risk | 2004 |
Adjusting the dose of low molecular weight heparins in renally impaired and obese patients.
Topics: Anticoagulants; Biomarkers; Cardiovascular Diseases; Comorbidity; Creatinine; Dose-Response Relationship, Drug; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Kidney Diseases; Metabolic Clearance Rate; Obesity; Renal Dialysis; Retrospective Studies | 2004 |
Massive rectus sheath hematoma.
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Enoxaparin; Epigastric Arteries; Female; Hematoma; Humans; Rectus Abdominis; Tomography, X-Ray Computed | 2006 |
Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Topics: Angina, Unstable; Angioplasty; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Bypass; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Treatment Outcome | 2000 |
Depo-heparin for long term therapy of myocardial infarction.
Topics: Cardiovascular Diseases; Dalteparin; Heparin; Humans; Myocardial Infarction | 1952 |